课题基金 / 基金详情

COVID-19: Role of naïve T cells, Age associated T cell senescence, and Dysfunctional Immune regulation in host response to SARS-CoV-2

COVID-19: Role of naïve T cells, Age associated T cell senescence, and Dysfunctional Immune regulation in host response to SARS-CoV-2
COVID-19:幼稚 T 细胞、年龄相关 T 细胞衰老和免疫调节功能失调在宿主对 SARS-CoV-2 反应中的作用
批准号:
10152273
负责人:
Donald D Anthony
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2023-03-31

项目摘要

项目成果

Donald D Anthony的其他基金

相似基金

相关文献

中文摘要
翻译
SARS-CoV-2的全球大流行呈现出高传染性和高风险的不幸组合。 自1917-1918年流感以来从未见过的一种引起世界范围后果的病态RNA病毒病原体 流行病这突出表明迫切需要一种预防或减轻疾病的疫苗。了解 自然宿主对SARS-CoV-2的免疫反应与临床结果有关,这是我们目前研究的中心。 在我们着手为第一轮很可能不太理想的效果做准备时, 疫苗了解宿主免疫反应的特点,之前和参与决定这一点, 需要临床结果的异质性来指导我们改进第二轮疫苗。T细胞 淋巴细胞减少症可能是与严重COVID-19发病率相关的一个因素。当然,T细胞和B细胞 细胞免疫是对大多数病毒的成功的长期应答所必需的。此外,我们和其他 已经描述了宿主T细胞免疫在老年个体中改变的许多特征, 病毒感染,包括淋巴细胞减少症、幼稚T细胞数量和功能缺陷、T细胞衰老和 紊乱的免疫调节我们将检验以下假设:在老年人中,IL-6和 sTNFR 2和较低频率的幼稚T细胞阻碍了对COVID-19的初始充分T细胞应答 感染,也与先前流感疫苗的抗体水平较低有关。衰老和 耗尽的T细胞和T细胞功能障碍损害了对SARS-CoV-2的Th 1记忆反应的发展, 预测病态的COVID-19结果。我们将确定是否老年、IL-6、sTNFR 2或较低的初治 COVID-19暴露前的CD 4 T细胞数量/功能与宿主T和B细胞应答相关 先前的流感疫苗和/或对SARS的有效宿主Th 1细胞应答的发展受损- COV-2和临床COVID-19结果的严重程度;并确定是否年龄较大和疲惫, COVID-19暴露前后存在的衰老或异常Treg细胞表型与 较低的SARS-CoV-2 Th 1记忆应答和/或宿主T细胞和抗体应答, 流感疫苗。
英文摘要
The global pandemic of SARS-CoV-2 presents the unfortunate combination of a highly contagious and highly morbid RNA virus pathogen that is responsible for a world-wide outcome not seen since the 1917-1918 flu pandemic. This highlights the urgent need for a vaccine that prevents or mitigates disease. Understanding the natural host immune response to SARS-CoV-2 as it relates to clinical outcome is at the center of our current needed perspective as we embark on preparing for the very likely, less than ideal effectiveness on initial round vaccine. Understanding host immune response features that precede and participate in determining this heterogeneity in clinical outcome is needed to guide us forward to an improved second round vaccine. T cell lymphopenia may be one factor that correlates with severe COVID-19 morbidity. Certainly, both T cell and B cell immunity are required for a successful long term response to most all viruses. Additionally, we and others have described a number of features of host T cell immunity altered in older aged individuals with and without viral infection, including lymphopenia, naïve T cell numerical and functional defects, T cell senescence and deranged immune regulation. We will examine the hypothesis that: In the elderly, higher levels of IL-6 and sTNFR2, and lower frequencies of naïve T cells preclude initial adequate T cell responses to COVID-19 infection and are also associated with lower antibody levels to prior Influenza vaccine. Senescent and exhausted T cells and dysfunction in Tregs impair development of Th1 memory responses to SARS-CoV-2 and predict morbid COVID-19 outcome. We will Determine whether older age, IL-6, sTNFR2, or lower naïve CD4 T cell number/function prior to COVID-19 exposure is associated with host T and B cell response to prior influenza vaccine and/or impaired development of effective host Th1 cell response to SARS- Cov-2 and severity of clinical COVID-19 outcomes; and Determine whether older age and exhausted, senescent or aberrant Treg cell phenotype present before or after COVID-19 exposure is associated with lower SARS-CoV-2 Th1 memory response and/or host T cell and antibody response to prior influenza vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COVID-19: Role of naïve T cells, Age associated T cell senescence, and Dysfunctional Immune regulation in host response to SARS-CoV-2
Impact of Immune Activation on Cardiovascular and Immune Health in RA
Impact of Immune Activation on Cardiovascular and Immune Health in RA
ShEEP Request for 5 Laser 28 parameter Flow Cytometer
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: